Multizentrische, kontrollierte Pharmakotherapie Studien in der Indikation Parkinson Syndrome der German Parkinson Study Group

GPS Studien rekrutierend und laufend. Stand 10/2025

	Indikation	Studientitel	Neuroprotektion/Symptom.	Prüfsubstanz	Clin.Trial/EudraCT	Primäres Zielkriterium	Status	Zentren Liste	Phase
1a	PK	A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80	Neuroprotektion	BIIB122 LUMA PD	NCT05348785	To evaluate the efficacy and safety of BIIB122 225 mg on desease progression by the time to confirmed worsening in MDS-UPDRS Parts II and III combined score over the treatment period (minimum 48 weeks, maximum 144 weeks) in PD patients	Acive,not recruiting	Paracelsus-Elena-Klinik Kassel Univ. Klinik Marburg Univ. Klinik Ulm Univ. Klinik Dresden Kath. Klinikum Bochum Univ. Klinik Lübeck LMU Klinikum München TU Klinikum München Univ. Klinik Tübingen Univ. Klinik Düsseldorf Univ. Klinik Würzburg Kath. Klinikum Bochum Univ. Klinik Hannover	Phase 2
1b	PK	A Study to Assess the Safety and pharmakodynamic effects of BIIB122 in patients with LRRK2-associated PD	Neuroprotektion	BIIB122	NCT06602193	A Study to Assess the Safety and pharmakodynamic effects of BIIB122 in patients with LRRK2-associated PD over 12-weeks followed by OLE	Recruiting	Univ. Klinik Dresden Univ. Klinik Lübeck Univ. Klinik Tübingen	Phase 2a
2	PK	Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE)	Neuroprotektion	BIA 28-6156	NCT05819359	The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).	Acive,not recruiting	Neurol. Fach KH Beelitz Gertrudis Klinik Biskirchen Paracelsus-Elena-Klinik Kassel Univ. Klinikum Marburg LMU Klinikum München Parkinson-Klinik Ortenau	Phase 2
3	PK	Safety, Tolerability and Symptomatic Efficacy of the ROCKInhibitor Fasudil in Patients with Parkinson's Disease (ROCK-PD)	Neuroprotektion	Fasudil	NCT05931575	To establish the combined safety and/or tolerability profile of oral Fasudil solution over 22 days in PD patients	Recruiting	Univ. Klinik Dresden Univ. Klinik Tübingen Univ. Klinik Münster Univ. Klinik Ulm Univ. Klinik München Univ. Klinik Würzburg Univ. Klinik Bochum Univ. Klinik Leipzig Univ. Klinik Marburg Univ. Klinik Kiel Univ. Klinik Düsseldorf Univ. KlinikGöttingen Univ. Klinik Freiburg	Phase 2
4	MSA	A Study of TAK-341 in Treatment of Multiple System Atrophy	Neuroprotektion	TAK-341	NCT05526391	To evaluate the efficacy of TAK-341 versus placebo, as measured by the change from baseline to Week 52 on UMSARS Part I in participants with MSA	Completed	Paracelsus Elena Klinik Kassel Univ. Klinik Leipzig Univ. Klinik Hannover Univ. Klinik Münster St. Josef Hosp. Bochum Uni. Klinik Dresden Bonn Deutsches Zentr. F. Neurodeg. Erkrankungen Univ. Klinik Charité Berlin Univ. Klinik Marburg Univ. Klinik München, Univ. Klinik Ulm; Univ. Klinik Tübingen	Phase 2
5	MSA	Study to Evaluate the Safety , Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)	Neuroprotektion	ION464 HORIZON	NCT04165486	The primary objective of the MAD part of the study is to evaluate the safety and tolerability of multiple doses of BIIB101/ION464 administered via IT bolus injection to participants with MSA.	Recruiting	Univ. Klinik Düsseldorf Univ. Klinik Hannover Univ. Klinik Ulm Univ. Klinik Marburg	Phase 1
6	MSA	A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients with Multiple System Atrophy TOPAS-MSA	Neuroprotektion	TEV-56286	NTC06568237	A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients with MSA over 56 weeks	Recruiting	Beelitz Heilstätten Univ. Klinik Düssledorf Paracelsus Elena Klinik Kassel Univ. Klinik Leipzig Univ. Klinik Münster Uni. Klinik Dresden Univ. Klinik Marburg Univ. Klinik München, Univ. Klinik Ulm; Univ. Klinik Tübingen	Phase 2
7	PSP	Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy	Neuroprotektion	NIO752	NCT04539041	Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy Phase 1	Completed	Univ. Klinik Düsseldorf Univ. Klinik Hannover LMU Klinikum München Univ. Klinik Tübingen Univ. Klinik Ulm	Phase 1
8	PSP	A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy	Neuroprotektion	UCB0107 (Bepranemab)	NCT04658199	The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with PSP.	Acive,not recruiting	Univ. Klinik Bochum Univ. Klinikum Düsseldorf Univ. Klinik Essen Univ. Klinik Hannover	Phase 1
9	PSP	AMX0035 and Progressive Supranuclear Palsy (ORION)	Neuroprotektion	AMX0035	NCT06122662	A3S-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.	Acive,not recruiting	Univ. Klinik Ulm, Krankenhaus Agatharied LMU Klinikum München, Paracelsus-Elena-Klinik Kassel	Phase 2/3
10	PSP	A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy	Neuroprotektion	FNP-223	NCT06355531	PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.	Acive,not recruiting	LMU Klinikum München, weitere Zentren im Verlauf	Phase 2

GPS Studien in 2024/2025 angefragt und in der Planung. Stand 10/2025

1	PK	A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson's Disease	Neuroprotektion	Biohaven BHV8000-301	NCT06976268	To evaluate the efficacy of BHV-8000 compared to placebo on the change from baseline to Week 48 on the MDS-UPDRS Part III.	Planning		Phasse 2/3
2	PK	A phase II, random. , doppel-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of SENLOFLAST in participants with early PD	Neuroprotektion	Roche BP45960		To evaluate the efficacy of selnoflast compared with placebo in participants with early-stage PD on stable treatment with levodopa over 104 weeks	Planning		Phase 2/3
3	PK	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease	Neuroprotektion	Roche BN44715	NCT07174310	To Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease on stable symptomatic monotherapy with levodopa	Planning		Phase 3
4	LBD	A Double blind, Placebo-controlled, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) and Extension Study	Neuroprotektion	ACP-204-012/ ACP-204_013	NCT 07029581		Planning		Phase 2/3
5	PSP	A multicenter, randomized, double-blind, parallel group, placebo-controlled adaptive phase 2/3 clinical trial with an open-label extension to assess safety and efficacy of AZP2006 in patients with progressive supranuclear palsy Promise-PSP Trial	Neuroprotektion	AZP2006	NCT07173803		Planning		Phase 2/3